JP2016519106A5 - - Google Patents

Download PDF

Info

Publication number
JP2016519106A5
JP2016519106A5 JP2016507631A JP2016507631A JP2016519106A5 JP 2016519106 A5 JP2016519106 A5 JP 2016519106A5 JP 2016507631 A JP2016507631 A JP 2016507631A JP 2016507631 A JP2016507631 A JP 2016507631A JP 2016519106 A5 JP2016519106 A5 JP 2016519106A5
Authority
JP
Japan
Prior art keywords
compound
glycine
use according
bond
phenylalanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016507631A
Other languages
English (en)
Japanese (ja)
Other versions
JP6420314B2 (ja
JP2016519106A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/033476 external-priority patent/WO2014169026A1/en
Publication of JP2016519106A publication Critical patent/JP2016519106A/ja
Publication of JP2016519106A5 publication Critical patent/JP2016519106A5/ja
Application granted granted Critical
Publication of JP6420314B2 publication Critical patent/JP6420314B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016507631A 2013-04-10 2014-04-09 Metap2阻害剤及び肥満症の治療方法 Active JP6420314B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361810468P 2013-04-10 2013-04-10
US61/810,468 2013-04-10
US201461925918P 2014-01-10 2014-01-10
US61/925,918 2014-01-10
PCT/US2014/033476 WO2014169026A1 (en) 2013-04-10 2014-04-09 Metap2 inhibitors and methods of treating obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018192578A Division JP2019023219A (ja) 2013-04-10 2018-10-11 Metap2阻害剤及び肥満症の治療方法

Publications (3)

Publication Number Publication Date
JP2016519106A JP2016519106A (ja) 2016-06-30
JP2016519106A5 true JP2016519106A5 (https=) 2017-04-13
JP6420314B2 JP6420314B2 (ja) 2018-11-07

Family

ID=51686946

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016507631A Active JP6420314B2 (ja) 2013-04-10 2014-04-09 Metap2阻害剤及び肥満症の治療方法
JP2018192578A Pending JP2019023219A (ja) 2013-04-10 2018-10-11 Metap2阻害剤及び肥満症の治療方法
JP2021043481A Pending JP2021091738A (ja) 2013-04-10 2021-03-17 Metap2阻害剤及び肥満症の治療方法
JP2023061783A Active JP7681054B2 (ja) 2013-04-10 2023-04-05 Metap2阻害剤及び肥満症の治療方法
JP2025078682A Pending JP2025109807A (ja) 2013-04-10 2025-05-09 Metap2阻害剤及び肥満症の治療方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018192578A Pending JP2019023219A (ja) 2013-04-10 2018-10-11 Metap2阻害剤及び肥満症の治療方法
JP2021043481A Pending JP2021091738A (ja) 2013-04-10 2021-03-17 Metap2阻害剤及び肥満症の治療方法
JP2023061783A Active JP7681054B2 (ja) 2013-04-10 2023-04-05 Metap2阻害剤及び肥満症の治療方法
JP2025078682A Pending JP2025109807A (ja) 2013-04-10 2025-05-09 Metap2阻害剤及び肥満症の治療方法

Country Status (12)

Country Link
US (9) US9173956B2 (https=)
EP (2) EP2984085B1 (https=)
JP (5) JP6420314B2 (https=)
CN (2) CN105431426A (https=)
AU (1) AU2014250983B2 (https=)
BR (1) BR112015025892A2 (https=)
CA (1) CA2908993C (https=)
DK (2) DK3574922T3 (https=)
EA (1) EA033912B1 (https=)
ES (2) ES2902082T3 (https=)
MX (2) MX386958B (https=)
WO (1) WO2014169026A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2576638T3 (da) 2010-05-25 2021-03-15 Syndevrx Inc Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
CN105431426A (zh) 2013-04-10 2016-03-23 新德发制药有限公司 Metap2抑制剂和治疗肥胖症的方法
CN106432255A (zh) * 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CN108697807B (zh) * 2016-01-11 2021-11-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗
CN113453721B (zh) 2018-10-26 2025-09-16 辛德弗雷克斯公司 Metap2抑制剂的生物标志物及其应用
CN114573476B (zh) * 2020-09-14 2024-06-11 广州药本君安医药科技股份有限公司 线性头尾二胺桥连化合物及在制备治疗糖代谢紊乱疾病药物中的应用
CN118871428A (zh) * 2022-02-16 2024-10-29 耶路撒冷希伯来大学伊森姆研究发展有限公司 Metap2抑制剂及其用途

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803586A (en) 1953-06-29 1957-08-20 Abbott Lab ph control in production of fumagillin
GB8500209D0 (en) 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
US5166172A (en) 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US4997878A (en) 1988-12-29 1991-03-05 Exxon Research And Engineering Company Hydrophobically associating polymers containing dimethyl acrylamide functionality
US5258453A (en) 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
GB9320781D0 (en) 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
US20030220233A1 (en) 1994-01-24 2003-11-27 Neorx Corporation Radiolabeled annexins
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
TW409058B (en) 1996-06-06 2000-10-21 Daiichi Seiyaku Co Method for preparation of a drug complex
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
WO1999011272A1 (en) * 1997-09-02 1999-03-11 Johns Hopkins University School Of Medicine Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
US6306819B1 (en) 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
US6242494B1 (en) 1998-05-01 2001-06-05 Abbott Laboratories Substituted β-amino acid inhibitors of methionine aminopeptidase-2
KR100357542B1 (ko) 1998-05-15 2002-10-18 주식회사종근당 푸마질롤 유도체 및 그 제조방법
HK1040052B (zh) 1998-05-22 2006-09-15 第一制药株式会社 药物复合物
US6464850B1 (en) 1998-07-31 2002-10-15 Biowhittaker Molecular Applications, Inc. Method for producing hydrophilic monomers and uses thereof
ID29943A (id) 1998-10-30 2001-10-25 Daiichi Seiyaku Co Senyawa dds dan metode pengukurannya
EP1222217B1 (en) 1999-09-08 2005-06-15 Polytherics Limited Uniform molecular weight polymers
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US20020002152A1 (en) 2000-04-14 2002-01-03 Craig Richard A. Hydrazide and alkoxyamide angiogenesis inhibitors
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US20070161570A1 (en) * 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
EP1436286B1 (en) 2001-09-27 2009-08-19 Equispharm Co., Ltd. Fumagillol derivatives and preparing method thereof
WO2003070173A2 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003230852B2 (en) * 2002-04-11 2008-07-10 Children's Medical Center Corporation TNP-470 polymer conjugates and use thereof
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
US7030262B2 (en) 2002-08-06 2006-04-18 Abbott Laboratories 3-Amino-2-hydroxyalkanoic acids and their prodrugs
US20040116348A1 (en) 2002-09-23 2004-06-17 Ying Chau Polymer-linker-drug conjugates for targeted drug delivery
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040228831A1 (en) * 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
CN102321584B (zh) 2003-12-31 2014-01-08 宾夕法尼亚州研究基金会 预测并克服对卵巢癌化疗的抗性的方法及预测结肠癌发生的方法
US20070287680A1 (en) 2004-05-10 2007-12-13 University Of Utah Research Foundation Combined Active and Passive Targeting of Biologically Active Agents
US7214664B2 (en) 2004-12-03 2007-05-08 The Curators Of The University Of Missouri Peptidyl prodrugs that resist P-glycoprotein mediated drug efflux
CN101142210A (zh) * 2005-01-26 2008-03-12 株式会社钟根堂 烟曲霉醇衍生物或制备烟曲霉醇衍生物的方法、以及包含该衍生物的药物组合物
WO2006084054A2 (en) 2005-02-02 2006-08-10 Children's Medical Center Corporation Method of treating angiogenic diseases
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
WO2006124711A1 (en) 2005-05-16 2006-11-23 The Board Of Trustees Of The University Of Illinois Composition and method for providing localized delivery of a therapeutic agent
EP2170402B1 (en) 2007-06-26 2015-03-25 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US20090104210A1 (en) * 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
EP2217283A2 (en) 2007-11-28 2010-08-18 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
WO2009141826A2 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
DE102008027574A1 (de) 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
WO2010065877A2 (en) * 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
TWI373345B (en) * 2009-02-19 2012-10-01 Academia Sinica Breast cancer-targeting peptides and use thereof
EP2493497A4 (en) 2009-11-01 2013-07-24 Brigham & Womens Hospital NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME
WO2011127304A2 (en) * 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
US20110294952A1 (en) * 2010-05-25 2011-12-01 SynDevRX Optimized Drug Conjugates
DK2576638T3 (da) * 2010-05-25 2021-03-15 Syndevrx Inc Polymerkonjugerede metap2-inhibitorer og terapeutiske fremgangsmåder til anvendelse deraf
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US9173865B2 (en) * 2010-11-29 2015-11-03 Zafgen, Inc. Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
EP2683706B1 (en) * 2011-03-08 2018-02-21 Zafgen, Inc. Oxaspiro [2.5]octane derivatives and analogs
CN105431426A (zh) * 2013-04-10 2016-03-23 新德发制药有限公司 Metap2抑制剂和治疗肥胖症的方法
BR112017013574A2 (pt) 2014-12-23 2018-03-06 Verdon Daniel conjugados de aminoácido e peptídeo e usos dos mesmos
US9969722B2 (en) 2015-12-10 2018-05-15 Syndevrx, Inc. Fumagillol derivatives and polymorphs thereof
CN108697807B (zh) 2016-01-11 2021-11-26 辛德弗雷克斯公司 代谢功能障碍引起的肿瘤的治疗

Similar Documents

Publication Publication Date Title
JP2016519106A5 (https=)
JP2018518537A5 (https=)
RU2012128547A (ru) Дважды ацилированные производные glp-1
CA2711834C (en) Synthetic triterpenoids and methods of use in the treatment of disease
US12129247B2 (en) Administration regime for nitrocatechols
AU2019204493A1 (en) Pharmaceutical compositions comprising PPAR agonists and Nrf2 activators
JP2016527277A5 (https=)
JP2013537195A5 (ja) 疾患を治療するための医薬品及び同医薬品を含むキット
JP2015526458A5 (https=)
MX355361B (es) Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados.
JP2010523476A5 (https=)
AU2015353492A1 (en) Fatty acid cysteamine conjugates and their use as activators of autophagy
RU2012150108A (ru) Аналоги глюкагоноподобного пептида-1 и их применение
JP2019507781A5 (https=)
JP2013500304A5 (https=)
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
JP2010529203A5 (https=)
JP2008528658A5 (https=)
JP2016523241A5 (https=)
JP2013155195A5 (https=)
JP2007527919A5 (https=)
JP2018505859A5 (https=)
JP2016128399A5 (https=)
JP2013503110A5 (https=)
FI3746467T3 (fi) Muutetut lipidoidut relaksiinin b-ketjun peptidit ja niiden terapeuttinen käyttö